BMY rises 6.3% in a month as investors pin hopes on new drugs to offset pressure from pipeline and patent losses.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Bristol-Myers Squibb’s shares (currently trading at $46.80) have posted a disappointing 18% loss, well below the S&P 500’s ...

Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main ...

The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have ...

Bristol Myers Squibb is undervalued despite challenges. Learn how BMY stock's strong pipeline, cash flow, and growth strategies offset patent expiries.

Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bristol Myers and Pfizer said on Thursday they will start selling their blockbuster blood thinner, Eliquis, directly to ...

Bristol Myers and Pfizer will sell Eliquis directly to U.S. patients at a discounted rate with transparent pricing and ...

The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.

Bristol Myers Squibb said the U.S. Food and Drug Administration has accepted its application seeking expanded approval of its plaque psoriasis drug Sotyktu for the treatment of adults with active ...